EUCTR2013-000632-94-GB进行中（未招募）不适用
Efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes - SUSTAIN™ 1 – Monotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, age equal to or above 18 years at the time of signing informed consent
- •2. For Japan only: Male or female, age equal to or above 20 years at the time of signing informed consent
- •3. Subjects diagnosed with type 2 diabetes and treated with diet and exercise for at least 30 days before screening
- •4. HbA1c 7.0 – 10.0 % (53 - 86 mmol/mol) (both inclusive)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 312
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 78
排除标准
- •1. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period. United Kingdom: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is sole partner of subject), or true abstinence (when in line with preferred and usual lifestyle)
- •2. Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject’s safety or compliance with the protocol
- •3. Treatment with any glucose lowering agent(s) in a period of 90 days prior to screening. An exception is short-term treatment (equal to or less than 7 days in total) with insulin in connection with inter-current illness
- •4. History of chronic or idiopathic acute pancreatitis
- •5. Screening calcitonin value equal to or above 50 ng/L (pg/mL)
- •6. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2)
- •7. Impaired renal function defined as eGFR below 30 mL/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4 variable version)
- •8. Acute coronary or cerebrovascular event within 90 days before randomisation
- •9. Heart failure, New York Heart Association class IV
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetesMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2012-004827-19-BGovo Nordisk A/S1,200
已完成
3 期
A trial to evaluate the efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetesCTRI/2014/05/004626ovo Nordisk AS95
进行中（未招募）
不适用
Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2012-004826-92-HRovo Nordisk A/S798
进行中（未招募）
1 期
Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetesDiabetes Mellitus, Type 2MedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-004827-19-PTovo Nordisk A/S1,200
进行中（未招募）
1 期
Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetesMedDRA version: 16.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2012-004826-92-GRovo Nordisk A/S798